Inhibitory Effect of Ginkgolide B on Platelet Aggregation in a cAMP- and cGMP-dependent Manner by Activated MMP-9

Hyun-Jeong Cho¹ and Kyung-Soo Nam²,*

¹College of Medicine and Cardiovascular Medical Research Center, Dongguk University, Gyeongju 780-714, Republic of Korea
²Department of Pharmacology, College of Medicine, Dongguk University, Gyeongju 780-714, Republic of Korea

Received 22 January 2007, Accepted 10 April 2007

Extracts from the leaves of the Ginkgo Biloba are becoming increasingly popular as a treatment that is claimed to reduce atherosclerosis, coronary artery disease, and thrombosis. In this study, the effect of ginkgolide B (GB) from Ginkgo biloba leaves in collagen (10 µg/ml)-stimulated platelet aggregation was investigated. It has been known that human platelets release matrix metalloproteinase-9 (MMP-9), and that it significantly inhibited platelet aggregation stimulated by collagen. Zymographic analysis confirmed that pro-MMP-9 (92-kDa) was activated by GB to form an MMP-9 (86-kDa) on gelatinolytic activities. And then, activated MMP-9 by GB dose-dependently inhibited platelet aggregation, intracellular Ca²⁺ mobilization, and thromboxane A₂ (TX A₂) formation in collagen-stimulated platelets. Activated MMP-9 by GB directly affects down-regulations of cyclooxygenase-1 (COX-1) or TXA₂ synthase in a cell free system. In addition, activated MMP-9 significantly increased the formation of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), which have the anti-platelet function in resting and collagen-stimulated platelets. Therefore, we suggest that activated MMP-9 by GB may increase the intracellular cAMP and cGMP production, inhibit the intracellular Ca²⁺ mobilization and TXA₂ production, thereby leading to inhibition of platelet aggregation. These results strongly indicate that activated MMP-9 is a potent inhibitor of collagen-stimulated platelet aggregation. It may act a crucial role as a negative regulator during platelet activation.

Keywords: Cyclic nucleotide, Ginkgolide B, Intracellular Ca²⁺, Matrix metalloproteinase-9, Platelet aggregation

Introduction

Ginkgo biloba, a Chinese herb, has been used in traditional Chinese medicine for thousands of years (Kleijnen and Knipschild, 1992). It is of great interest because its leaves possess pharmacological properties that include radical scavenging, blood flow improvement, vasoprotection, and anti-platelet aggregating factor (PAF) activity (Dietz and De Feudis, 2000; Van Beek, 2000). In numerous experimental models, a ginkgo extract was found to affect vascular and metabolic disturbances as well as neurological and behavioral activities, especially dementia (Chatterjee, 1984; Karcher et al., 1984; Tang and Eisenbrand, 1992). Among the constituents of Ginkgo biloba, terpene trilactones such as bilobalide, ginkgolide A (GA), ginkgolide B (GB), ginkgolide C (GC), along with flavonoides, have been identified as the active constituents of the Ginkgo extract for inhibition of the binding of PAF (Braquet, 1986; Hasler, 2000). In this report, we investigated the anti-platelet mechanism of GB in collagen-stimulated platelets.

Matrix metalloproteinases (MMPs) are a family of Zn²⁺- and Ca²⁺-dependent enzymes, which are important in the resorption of extracellular matrices. It is known that MMPs have been implicated in the tissue remodeling, which accompanies inflammation, bone resorption, wound healing, thrombosis, atherosclerosis, and the invasion of tumors (Ray and Stetler-Stevenson, 1994). Most MMPs are synthesized and secreted as inactive proenzymes (Lijene, 2001). MMP-9, also known as gelatinase B, has a broad range of substrate specificity for different native collagens (types IV, VI, VII, and X) as well as denatured collagens (gelatine) and elastin (Ray and Stetler-Stevenson, 1994; Brikedal-Hansen, 1995). MMP-9 is secreted as a 92-kDa proenzyme and can be activated to be an 86-kDa active form (Brikedal-Hansen, 1995). Vascular smooth muscle and endothelial cells are known to synthesize and release MMPs including MMP-9 (Ray and Stetler-Stevenson, 1994; Sawicki et al., 1997), suggesting that this may be associated with the process of
hemostasis and thrombosis. Sheu et al. (2004) demonstrated that human platelets release MMP-9, and that activated MMP-9 significantly inhibited platelet aggregation stimulated by collagen. We therefore investigated the effect of MMP-9 on platelets, and found out the anti-platelet mechanism of GB from Ginkgo biloba in collagen-stimulated platelets.

Thrombosis plays an important role in the pathogenesis of acute coronary syndromes, and vessel wall injury leads to the adherence of platelets and subsequent platelet activation. Platelet aggregation is absolutely essential to the formation of a hemostatic plug when normal blood vessels are injured. However, the interactions between platelets and collagen can also cause circulatory disorders, such as thrombosis, atherosclerosis, and myocardial infarction (Schwartz et al., 1990). Inhibition of the platelet-collagen interaction might be a promising approach to the prevention of thrombosis. An important role in the mechanism by which collagen induces platelet aggregation is played by thromboxane A2 (TXA2) formation (Cattaneo et al., 1991), which also contributes to an increase in cytosolic free Ca2+ level ([Ca2+]i) in collagen-activated platelets. An increase in [Ca2+]i activates both the Ca2+/calmodulin-dependent phosphorylation of myosin light chain (20-kDa) and the diacylglycerol-dependent phosphorylation of cytosolic protein (40- or 47-kDa) to induce platelet aggregation (Kaibuchi et al., 1982; Nishikawa et al., 1980). In addition, diacylglycerol also can be hydrolyzed by diacylglycerol lipase to produce arachidonic acid (20:4), a precursor of TXA2, which is a potent platelet aggregation agent generated from 20:4 lipids when PIP2 is broken down by collagen, thrombin and ADP (Nishikawa et al., 1980; Kaibuchi et al., 1982; Menshikove et al., 1993). Verapamil and theophylline have an anti-platelet function that elevates the cyclic adenosine monophosphate (cAMP) level, and then decreases the [Ca2+]i, an essential factor for platelet aggregation. Vasodilators (such as molsidomine and nitroprusside) and cyclic guanosine monophosphate (cGMP) phosphodiesterase (PDE) inhibitors (such as zaprinast and erythro-9-[2-hydroxy-3-nonyl]adenine) elevate cGMP levels in platelets, decreases agonist-elevated [Ca2+]i, activates both the cyclooxygenase-1 (COX-1) or TXA2 synthase in collagen-stimulated human platelet aggregation.

Materials and Methods

Materials. GB (Fig. 1) from Ginkgo biloba leaves was purchased from the Sigma-Aldrich Co., and collagen was obtained from the Sigma-Aldrich Co., and collagen was obtained from Bio-Rad Laboratories. Fura-2-AM was obtained from Sigma Chemical Co. cAMP- and cGMP-enzymeimmunoassay (EIA) kits were purchased from R&D systems, Inc. and a TXB2-EIA system were obtained from Amersham Bioscience.

Preparation of washed rat platelets. Blood was collected from Sprague-Dawley rats (6-7 weeks, male), and anti-coagulated with ACD solution (0.8% citric acid, 2.2% sodium citrate, 24% glucose). Platelet-rich plasma was centrifuged at 12,500 x g for 10 min to remove the red blood cells, and the platelets were washed twice with washing buffer (138 mM NaCl, 2.7 mM KCl, 12 mM NaHCO3, 0.36 mM NaH2PO4, 5.5 mM glucose, and 1 mM EDTA, pH 7.4). The washed platelets were then suspended in suspending buffer (138 mM NaCl, 2.7 mM KCl, 12 mM NaHCO3, 0.36 mM NaH2PO4, 0.49 mM MgCl2, 5.5 mM glucose, 0.25% gelatin, pH 7.4) to a final concentration of 5 x 108/ml. All of the procedures above were carried out at 25°C to avoid platelet aggregation on cooling.

Measurement of platelet aggregation. Washed platelets (108/ml) were preincubated for 5 min at 37°C in the presence of 2 mM of exogenous CaCl2 with or without GB and then stimulated with 10 μg of collagen/ml for 5 min. Aggregation was monitored using an aggregometer (Chrono-Log, Corp.) at a constant stirring speed of 1,000 rpm. Each aggregation rate was evaluated as an increase in light transmission. The suspending buffer was used as reference. GB was dissolved in dimethylsulfoxide (DMSO) (0.001%), and subtracted the effect of DMSO from the results.

Zymography of MMP-9. Washed platelets (108/ml) were preincubated for 5 min at 37°C with various concentrations of GB in the presence of 2 mM CaCl2 and then stimulated with 10 μg of collagen/ml for 5 min for zymography. The platelets were lysed on ice for 1 h in RIPA buffer (150 mM NaCl, 1% NP40, 0.1% SDS, 30 mM Tris, pH 8.0, 0.5% Deoxycholic acid) that contained a protease inhibitor, 0.5 mM sodium orthovanadate, and 1 mM phenylmethylsulphonylFluoride (PMSF), and centrifuged at 14000 x g at 4°C for 30 min. Supernatant was used as the cytosol fraction for the detection of activated MMP-9. Gelatin zymography was performed to detect MMP-9 activity in the extracted samples from rat platelets. Proteins in a sample were separated by sodium dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE) using 10% gels containing 1 mg/ml gelatin. Samples (25 μg proteins) were electrophoresed at 120 V for 90 min. The gels were washed with 2.5% Triton X-100 for 1 h, and then incubated with developing buffer (30 mM Tris-HCl, 5 mM CaCl2, 0.02% NaN3,
1 mM ZnCl2, pH7.5) at 37°C for 24 h. The gels were stained with 2.5% Coomassie Blue R-250 in 50% methanol and 10% acetic acid for 20 min, and destained in 30% methanol and 10% acetic acid solution, until active bands become clear. The digested area appeared clear on a blue background indicating the location of gelatinase.

**Measurement of cAMP and cGMP.** Washed platelets (10⁶/ml) were preincubated for 3 min at 37°C with various concentrations of GB in the presence of 2 mM CaCl₂ and then stimulated with 10 µg of collagen/ml for 5 min for platelet aggregation. The aggregation was terminated by adding 80% ice-cold ethanol. cAMP and cGMP were measured using the respective EIA kits of cAMP and cGMP. Because GB was dissolved in DMSO, respectively, the levels of cAMP and cGMP were calculated by subtracting the effect of DMSO, respectively.

**Statistical analysis.** All data are shown as means ± S.D. Student’s t-test was used for data analysis and paired or unpaired comparison was used where necessary.

**Results and Discussion**

**Inhibitory effect of GB on platelet aggregation.** In this study, we used GB (Fig. 1) from *Ginkgo biloba* leaves, a traditional Chinese medicine, to investigate the anti-platelet function. The concentration of collagen that induced maximal platelet aggregation was approximately 10 µg/ml (Cho et al., 2004). Therefore, 10 µg of collagen/ml was used as a platelet agonist in this study. Since [Ca²⁺]i, a critical regulator of platelet function, was terminated by adding 80% ice-cold ethanol. cAMP and cGMP were measured using the respective EIA kits of cAMP and cGMP. Because GB was dissolved in DMSO, respectively, the levels of cAMP and cGMP were calculated by subtracting the effect of DMSO, respectively.

**Measurement of TXB₂.** Washed platelets (10⁶/ml) were then preincubated with or without GB for 3 min in the presence of 2 mM CaCl₂ and activated for 5 min with 10 µg/ml of collagen. The reactions were terminated by adding ice-cold 5 mM EDTA and 0.2 mM indomethacin. The amount of TXB₂, a stable metabolite of TXA₂, was determined using a TXB₂ EIA kit. To determine the direct effects of GB on 20:4 metabolism, the cells were first sonicated with a sonicator (Bandein, HD2070, Germany) to obtain platelet lysates. The platelet lysates were incubated with various concentrations of GB for 5 min, and then 100 pmol of 20:4 was added to 200 µl of the lysate. The lysate mixtures were incubated further for 10 min, and the amount of TXB₂ was determined as described above.

**Effect of GB on MMP-9 activity in washed platelets.** Sheu et al. (2004) suggested that pro-MMP-9/activated MMP-9 is present in human platelets, and the inhibition of activated MMP-9 was demonstrable with the use of various agonists, such as collagen, thrombin, ADP, U46619, and arachidonic acid. Nakamura et al. (1998) suggested that human plasma MMP-9 concentrations ranged from 34.2 ± 16.6 to 52.4 ± 26.6 ng/ml. Sheu et al. (2004) indicated that cytoplasm was the main storage compartment for MMP-9 in resting and collagen-stimulated platelets. Therefore, we used the cytoplasm fraction to detect the MMP-9 activity. To determine whether platelet activation might cause changes in MMP-9 activity in the cytoplasm, we used the cell lysates treated with or without GB in the collagen-stimulated platelets. When platelets were preincubated with GB, GB concentration-dependently increased the activity of MMP-9 in collagen-stimulated platelets (Fig. 3). Zymographic analysis confirmed that pro-MMP-9 (92-kDa) was activated by GB (50 and 100 µM) to form an...
activated MMP-9 (86-kDa), as shown by gelatinolytic activities. These results suggest that the activated MMP-9 by GB may inhibit upstream of platelet aggregation when platelets were stimulated by collagen (10 µg/ml). Therefore, this partly indicates that activated MMP-9 may affect the cAMP or cGMP regulation, and this is in accord with the concept that intracellular cAMP and cGMP level are responsible for platelet aggregation (Sheu et al., 2004). Thus, we measured the cAMP and cGMP production by GB in resting and collagen-stimulated platelets.

Effects of GB on the formation of cAMP and cGMP: The elevation of the platelet activating reagent-induced aggregation is known to be lowered by either the production of cGMP or cAMP (Jang et al., 2002). We next investigated whether GB up-regulated the cellular level of cAMP/cGMP, endogenous negative regulators of platelet aggregation (Qi et al., 1996; Homer and Wanstall, 2002; Park et al., 2004). As shown in Fig. 4A, collagen decreased intracellular cAMP level from 4.9 ± 0.5 pmol/10⁶ platelets in comparison with the control levels (4.9 ± 0.5 pmol/10⁶ platelets) in resting platelets (Fig. 4A). It is interesting to note that GB modulated the production of cAMP in resting and collagen-stimulated platelets.

As shown in Fig. 4B, collagen decreased intracellular cGMP level from 6.2 ± 0.2 pmol/10⁶ platelets (basal level), to 4.7 ± 0.3 pmol/10⁶ platelets in washed platelets. When the platelets, however, were incubated in the presence of both GB and collagen, GB (10 to 500 µM) significantly increased the cGMP level in a dose-dependent manner. With the change of cAMP level in platelets, GB alone also increased the level of cGMP in resting platelets (Fig. 4B). These results indicate that GB regulates the production of cGMP in resting and collagen-stimulated platelets.

Above results suggest that GB might directly affect the activity of adenylate cyclase and cAMP-dependent PDE as well as guanylate cyclase and cGMP-dependent PDE. The increased cAMP and cGMP levels participate in activating PKA and PKG and consequently these enzymes phosphorylate their substrate proteins, resulting in negative regulation of platelet aggregation. The negatively regulated substrate proteins include vasodilator-stimulated phosphoprotein, a regulator of actin dynamics (Sudo et al., 2003), IP₃ receptor (Komalvils and Lincoln, 1994), and TXA₂ receptor (Kinsella et al., 1994). Therefore, GB might block the platelet aggregation via enhanced levels of cAMP and cGMP and its linked PKA/PKG activity. In other words, the activated MMP-9 by GB (Fig. 3) increased the intracellular cAMP and cGMP levels to inhibit the collagen-stimulated platelet aggregation (Fig. 4).

Effects of GB on the regulation of aggregation-inducing molecules, [Ca²⁺], and TXA₂: Of several aggregation-inducing molecules, Ca²⁺ and TXA₂ are known to be essential for platelet aggregation (Chung et al., 1997). Collagen-activated platelets require an adequate concentration of intracellular Ca²⁺ for aggregation, because the formation of platelet is accompanied by the migration of platelets and their adhesion. As shown in Fig. 5A, when washed platelets (10⁸/ml) were stimulated by collagen (10 µg/ml), the level of [Ca²⁺] increased from 75 to 672 nM. However, this was significantly reduced by various concentrations (10, 50, and 100 µM) of GB in a dose-dependent manner (87% inhibition at 100 µM), suggesting that the inhibitory activity of GB on collagen-stimulated platelet aggregation was due to lowering of the level of [Ca²⁺]. Therefore, GB significantly blocked Ca²⁺ release seemed to be critical to the GB-mediated inhibition of platelet aggregation (Fig. 5A).

TXA₂ is a potent stimulus of platelet aggregation, and its receptor G-protein (Gq)-PLC-iP, signaling pathway is activated by collagen treatment (Wang et al., 1998). Therefore, we next examined whether GB blocked the production of TXA₂ under collagen exposure. The TXA₂ (determined as TXB₂) level in intact platelets was 1.5 ± 0.3 pg/10⁶ platelets, and this was...
markedly increased to 7.2 ± 0.4 pg/10^5 platelets in the collagen-stimulated platelets (Fig. 5B). However, GB significantly reduced the production of TXA2 in a dose-dependent manner (75% inhibition at 100 µM). To determine if the inhibitory effect on TXA2 release of GB was due to the direct suppression of COX-1 or TXA2 synthase, cell-free enzyme assay method was used. When platelet lysates were incubated with or without GB (100 µM) for 5 min at 37°C in the presence of AA (20:4), a substrate of COX-1, GB treatment almost inhibited the TXA2 production (99.5% inhibition at 100 µM) as compared with intact platelets (Fig. 5C), suggesting that the decrease in TXA2 production by GB possibly is directly related to inhibition of its metabolic enzyme, COX-1 or TXA2 synthase.

In conclusion, the most important thing of this study suggested that GB significantly inhibit the collagen-stimulated platelet aggregation. GB increases both intracellular cAMP and cGMP level and MMP-9 activity, thereby leading to inhibition of the TXA2 production and intracellular Ca^{2+}-mobilization. Moreover, GB directly diminished the COX-1 or TXA2 synthase activity, resulting in decrease TXA2 formation, an aggregation-inducing molecule, ultimately leading to inhibition of intracellular TXA2-mediated Ca^{2+}-mobilization and platelet aggregation. Therefore, GB may inhibit the vascular disease associated with platelet aggregation, such as atherosclerosis, myocardial infarction, coronary artery disease, and thrombosis. These results suggest that GB may be a physiologically effective negative feedback regulator during the platelet aggregation.

Acknowledgments This work was supported by the Medical science and Engineering Research Centers (MRC) program from Ministry of Science and Technology (MOST)/Korea
References


